



## **AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference**

December 18, 2024

VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.

A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at <https://ir.avitamedical.com>. A replay of the webcast will be available following the conclusion of the event.

### **About AVITA Medical, Inc.**

AVITA Medical<sup>®</sup> is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL<sup>®</sup> System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin<sup>™</sup> Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm<sup>®</sup>, a biosynthetic wound matrix, and Cohealyx<sup>™</sup>, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO<sup>™</sup>, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit [www.avitamedical.com](http://www.avitamedical.com).

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Investor & Media Contact: Jessica Ekeberg Phone +1-661-904-9269 [investor@avitamedical.com](mailto:investor@avitamedical.com) [media@avitamedical.com](mailto:media@avitamedical.com)